Nine Masts Capital »

Black Diamond Therapeutics shares owned by Nine Masts Capital

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Nine Masts Capital from 13F filings

Historical chart of Nine Masts Capital investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Nine Masts Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Nine Masts Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $38k 18k 2.13

More positions owned by Nine Masts Capital

State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Alibaba Group Hldg Note 0.500% 6/0 (Principal)
Alphabet Cap Stk Cl C (GOOG)
Warner Bros Discovery Com Ser A (WBD)
Silicon Laboratories (SLAB)
Hdfc Bank Sponsored Ads (HDB)
Electronic Arts (EA)
Fox Corp Cl B Com (FOX)
Norfolk Southern (NSC)
Clearwater Analytics Hldgs I Cl A (CWAN)
Webster Financial Corporation (WBS)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Hologic
Nio Note 4.625%10/1 (Principal)
Ase Technology Hldg Sponsored Ads (ASX)

View all positions for Nine Masts Capital

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
NEA Management Company
Acadian Asset Management
Vanguard Group
Dimensional Fund Advisors
Marshall Wace
BlackRock
Connor, Clark & Lunn Investment Management
Siren
Arrowstreet Capital, Limited Partnership
Renaissance Technologies
Mackenzie Financial
Goldman Sachs Group
Citadel Advisors
UBS Group

View all funds holding Black Diamond Therapeutics